IQVIA (IQV) 10-Q 22 Oct 20 2020 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Sep. 30, 2020	Oct. 16, 2020
Document Information
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2020
Document Transition Report	false
Entity File Number	001-35907
Entity Registrant Name	IQVIA HOLDINGS INC.
Entity Incorporation, State	DE
Entity Tax Identification Number	27-1341991
Entity Address, Street	4820 Emperor Blvd.
Entity Address, City	Durham
Entity Address, State	NC
Entity Address, Postal Zip Code	27703
City Area Code	919
Local Phone Number	998-2000
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Title of Each Class	Common Stock, par value $0.01 per share
Trading Symbol	IQV
Name of Each Exchange on which Registered	NYSE
Entity Common Stock, Shares Outstanding		191,725,778
Current Fiscal Year End Date	--12-31
Entity Central Index Key	0001478242
Amendment Flag	false
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Principal Executive Offices
Document Information
Entity Address, Street	83 Wooster Heights Road
Entity Address, City	Danbury
Entity Address, State	CT
Entity Address, Postal Zip Code	06810
City Area Code	203
Local Phone Number	448-4600

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Income Statement [Abstract]
Revenues	$ 2,786	$ 2,769	$ 8,061	$ 8,193
Costs of revenue, exclusive of depreciation and amortization	1,800	1,852	5,328	5,399
Selling, general and administrative expenses	460	395	1,298	1,250
Depreciation and amortization	319	299	943	888
Restructuring costs	20	19	50	45
Income from operations	187	204	442	611
Interest income	(1)	(3)	(4)	(7)
Interest expense	100	114	314	338
Loss on extinguishment of debt	0	24	12	24
Other income, net	(14)	0	(59)	0
Income before income taxes and equity in earnings of unconsolidated affiliates	102	69	179	256
Income tax (benefit) expense	(3)	(1)	9	48
Income before equity in earnings of unconsolidated affiliates	105	70	170	208
Equity in earnings (loss) of unconsolidated affiliates	3	(1)	8	(1)
Net income	108	69	178	207
Net income attributable to non-controlling interests	(7)	(12)	(18)	(32)
Net income attributable to IQVIA Holdings Inc.	$ 101	$ 57	$ 160	$ 175
Earnings per share attributable to common stockholders:
Basic (in dollars per share)	$ 0.53	$ 0.29	$ 0.84	$ 0.89
Diluted (in dollars per share)	$ 0.52	$ 0.29	$ 0.82	$ 0.87
Weighted average common shares outstanding:
Basic (in shares)	191.3	194.5	191.3	195.9
Diluted (in shares)	194.9	199	194.9	200.5

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Statement of Comprehensive Income [Abstract]
Net income	$ 108	$ 69	$ 178	$ 207
Comprehensive income (loss) adjustments:
Unrealized (losses) gains on derivative instruments, net of income tax (benefit) expense of $(8), $(2), $(11), $(7)	(1)	(5)	(33)	(23)
Foreign currency translation, net of income tax expense (benefit) of $(54), $57, $(83), $65	130	(162)	20	(131)
Reclassification adjustments:
Losses (gains) on derivative instruments included in net income, net of income tax expense (benefit) of $1, $—, $2, $(1)	2	2	6	(2)
Comprehensive income (loss)	239	(96)	171	51
Comprehensive income attributable to non-controlling interests	(11)	(9)	(17)	(29)
Comprehensive income (loss) attributable to IQVIA Holdings Inc.	$ 228	$ (105)	$ 154	$ 22

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Statement of Comprehensive Income [Abstract]
Unrealized (losses) gains on derivative instruments, income tax (benefit) expense	$ (8)	$ (2)	$ (11)	$ (7)
Foreign currency translation, income tax expense (benefit)	(54)	57	(83)	65
Income tax (benefit) expense	$ 1	$ 0	$ 2	$ (1)

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Sep. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 1,464	$ 837
Trade accounts receivable and unbilled services, net	2,414	2,582
Prepaid expenses	165	138
Income taxes receivable	78	56
Investments in debt, equity and other securities	79	62
Other current assets and receivables	445	451
Total current assets	4,645	4,126
Property and equipment, net	452	458
Operating lease right-of-use assets	490	496
Investments in debt, equity and other securities	78	65
Investments in unconsolidated affiliates	85	87
Goodwill	12,363	12,159
Other identifiable intangibles, net	5,222	5,514
Deferred income taxes	125	119
Deposits and other assets	377	227
Total assets	23,837	23,251
Current liabilities:
Accounts payable and accrued expenses	2,461	2,512
Unearned income	1,188	1,014
Income taxes payable	101	108
Current portion of long-term debt	144	100
Other current liabilities	245	211
Total current liabilities	4,139	3,945
Long-term debt	12,195	11,545
Deferred income taxes	429	646
Operating lease liabilities	387	396
Other liabilities	580	456
Total liabilities	17,730	16,988
Commitments and contingencies
Stockholders’ equity:
Common stock and additional paid-in capital, 400.0 shares authorized at September 30, 2020 and December 31, 2019, $0.01 par value, 254.5 shares issued and 191.7 shares outstanding at September 30, 2020; 253.0 shares issued and 192.3 shares outstanding at December 31, 2019	11,070	11,049
Retained earnings	1,158	998
Treasury stock, at cost, 62.8 and 60.7 shares at September 30, 2020 and December 31, 2019, respectively	(6,065)	(5,733)
Accumulated other comprehensive loss	(317)	(311)
Equity attributable to IQVIA Holdings Inc.’s stockholders	5,846	6,003
Non-controlling interests	261	260
Total stockholders’ equity	6,107	6,263
Total liabilities and stockholders’ equity	$ 23,837	$ 23,251

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Common stock, shares authorized	400,000,000	400,000,000
Common stock, par value, usd per share	$ 0.01	$ 0.01
Common stock, shares issued	254,500,000	253,000,000
Common stock, shares outstanding	191,700,000	192,300,000
Treasury stock, shares	62,800,000	60,700,000

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Operating activities:
Net income	$ 178	$ 207
Adjustments to reconcile net income to cash provided by operating activities:
Depreciation and amortization	943	888
Amortization of debt issuance costs and discount	13	10
Stock-based compensation	69	87
(Earnings) loss from unconsolidated affiliates	(8)	1
Gain on investments, net	(17)	0
Benefit from deferred income taxes	(160)	(154)
Changes in operating assets and liabilities:
Change in accounts receivable, unbilled services and unearned income	328	(167)
Change in other operating assets and liabilities	(137)	(38)
Net cash provided by operating activities	1,209	834
Investing activities:
Acquisition of property, equipment and software	(440)	(445)
Acquisition of businesses, net of cash acquired	(118)	(461)
Purchases of marketable securities, net	(8)	(2)
Investments in unconsolidated affiliates, net of payments received	8	3
Investments in equity securities	(2)	(10)
Other	0	5
Net cash used in investing activities	(560)	(910)
Financing activities:
Proceeds from issuance of debt	1,591	1,900
Payment of debt issuance costs	(33)	(47)
Repayment of debt and principal payments on capital lease obligations	(792)	(875)
Proceeds from revolving credit facility	1,250	1,710
Repayment of revolving credit facility	(1,610)	(1,930)
(Payments) proceeds related to employee stock option plans	(43)
(Payments) proceeds related to employee stock option plans		15
Repurchase of common stock	(346)	(679)
Distributions to non-controlling interests, net	(16)	(6)
Contingent consideration and deferred purchase price payments	(20)	(21)
Net cash (used in) provided by financing activities	(19)	67
Effect of foreign currency exchange rate changes on cash	(3)	(19)
Increase (decrease) in cash and cash equivalents	627	(28)
Cash and cash equivalents at beginning of period	837	891
Cash and cash equivalents at end of period	$ 1,464	$ 863

CONDENSED CONSOLIDATED STATEM_5

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) shares in Millions, $ in Millions	Total	Common Stock	Treasury Stock	Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive (Loss) Income	Non- controlling Interests
Beginning balance at Dec. 31, 2018	$ 6,954	$ 3	$ (4,770)	$ 10,898	$ 807	$ (224)	$ 240
Beginning Balance, Shares at Dec. 31, 2018		251.5	(54)
Increase (Decrease) in Stockholders' Equity
Issuance of common stock	5			5
Issuance of common stock, Shares		0.7
Repurchase of common stock	(145)		$ (145)
Repurchase of common stock, Shares			(1)
Stock-based compensation	21			21
Net income	67				58		9
Unrealized losses on derivative instruments, net of tax	(5)					(5)
Foreign currency translation, net of tax	(31)					(32)	1
Reclassification adjustments, net of tax	(1)					(1)
Ending balance at Mar. 31, 2019	6,865	$ 3	$ (4,915)	10,924	865	(262)	250
Ending Balance, Shares at Mar. 31, 2019		252.2	(55)
Beginning balance at Dec. 31, 2018	6,954	$ 3	$ (4,770)	10,898	807	(224)	240
Beginning Balance, Shares at Dec. 31, 2018		251.5	(54)
Increase (Decrease) in Stockholders' Equity
Net income	207
Unrealized losses on derivative instruments, net of tax	(23)
Foreign currency translation, net of tax	(131)
Ending balance at Sep. 30, 2019	6,394	$ 3	$ (5,464)	10,987	982	(377)	263
Ending Balance, Shares at Sep. 30, 2019		252.8	(58.8)
Beginning balance at Mar. 31, 2019	6,865	$ 3	$ (4,915)	10,924	865	(262)	250
Beginning Balance, Shares at Mar. 31, 2019		252.2	(55)
Increase (Decrease) in Stockholders' Equity
Issuance of common stock	8			8
Issuance of common stock, Shares		0.4
Repurchase of common stock	(236)		$ (236)
Repurchase of common stock, Shares			(1.8)
Stock-based compensation	29			29
Distributions to non-controlling interests, net	(2)						(2)
Net income	71				60		11
Unrealized losses on derivative instruments, net of tax	(13)					(13)
Foreign currency translation, net of tax	62					63	(1)
Reclassification adjustments, net of tax	(3)					(3)
Ending balance at Jun. 30, 2019	6,781	$ 3	$ (5,151)	10,961	925	(215)	258
Ending Balance, Shares at Jun. 30, 2019		252.6	(56.8)
Increase (Decrease) in Stockholders' Equity
Issuance of common stock	(4)			(4)
Issuance of common stock, Shares		0.2
Repurchase of common stock	(313)		$ (313)
Repurchase of common stock, Shares			(2)
Stock-based compensation	30			30
Distributions to non-controlling interests, net	(4)						(4)
Net income	69				57		12
Unrealized losses on derivative instruments, net of tax	(5)					(5)
Foreign currency translation, net of tax	(162)					(159)	(3)
Reclassification adjustments, net of tax	2					2
Ending balance at Sep. 30, 2019	6,394	$ 3	$ (5,464)	10,987	982	(377)	263
Ending Balance, Shares at Sep. 30, 2019		252.8	(58.8)
Beginning balance at Dec. 31, 2019	$ 6,263	$ 3	$ (5,733)	11,046	998	(311)	260
Beginning Balance, Shares at Dec. 31, 2019	192.3	253	(60.7)
Increase (Decrease) in Stockholders' Equity
Issuance of common stock	$ (44)			(44)
Issuance of common stock, Shares		0.8
Repurchase of common stock	(332)		$ (332)
Repurchase of common stock, Shares			(2.1)
Stock-based compensation	7			7
Distributions to non-controlling interests, net	(5)						(5)
Net income	91				82		9
Unrealized losses on derivative instruments, net of tax	(39)					(39)
Foreign currency translation, net of tax	(155)					(151)	(4)
Reclassification adjustments, net of tax	16					16
Ending balance at Mar. 31, 2020	5,802	$ 3	$ (6,065)	11,009	1,080	(485)	260
Ending Balance, Shares at Mar. 31, 2020		253.8	(62.8)
Beginning balance at Dec. 31, 2019	$ 6,263	$ 3	$ (5,733)	11,046	998	(311)	260
Beginning Balance, Shares at Dec. 31, 2019	192.3	253	(60.7)
Increase (Decrease) in Stockholders' Equity
Net income	$ 178
Unrealized losses on derivative instruments, net of tax	(33)
Foreign currency translation, net of tax	20
Ending balance at Sep. 30, 2020	$ 6,107	$ 3	$ (6,065)	11,067	1,158	(317)	261
Ending Balance, Shares at Sep. 30, 2020	191.7	254.5	(62.8)
Beginning balance at Mar. 31, 2020	$ 5,802	$ 3	$ (6,065)	11,009	1,080	(485)	260
Beginning Balance, Shares at Mar. 31, 2020		253.8	(62.8)
Increase (Decrease) in Stockholders' Equity
Issuance of common stock	1			1
Issuance of common stock, Shares		0.3
Stock-based compensation	30			30
Net income	(21)				(23)		2
Unrealized losses on derivative instruments, net of tax	7					7
Foreign currency translation, net of tax	45					46	(1)
Reclassification adjustments, net of tax	(12)					(12)
Ending balance at Jun. 30, 2020	5,852	$ 3	$ (6,065)	11,040	1,057	(444)	261
Ending Balance, Shares at Jun. 30, 2020		254.1	(62.8)
Increase (Decrease) in Stockholders' Equity
Issuance of common stock	(3)			(3)
Issuance of common stock, Shares		0.4
Stock-based compensation	30			30
Distributions to non-controlling interests, net	(11)						(11)
Net income	108				101		7
Unrealized losses on derivative instruments, net of tax	(1)					(1)
Foreign currency translation, net of tax	130					126	4
Reclassification adjustments, net of tax	2					2
Ending balance at Sep. 30, 2020	$ 6,107	$ 3	$ (6,065)	$ 11,067	$ 1,158	$ (317)	$ 261
Ending Balance, Shares at Sep. 30, 2020	191.7	254.5	(62.8)

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies The Company IQVIA Holdings Inc. (together with its subsidiaries, the “Company” or “IQVIA”) is a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry. With approximately 68,000 employees, IQVIA conducts business in more than 100 countries. Unaudited Interim Financial Information The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair statement of the Company’s financial condition and results of operations have been included. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the year ending December 31, 2020. As such, the information included in this Quarterly Report on Form 10-Q should be read in conjunction with the Company’s audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019. The balance sheet at December 31, 2019 has been derived from the audited consolidated financial statements of the Company but does not include all the disclosures required by GAAP. Additionally, t he outbreak of the novel coronavirus, or COVID-19, and the various governmental, industry and consumer actions related thereto, could have a material and adverse effect on our business, financial condition and results of operations. These effects, which largely depend on future developments that cannot be accurately predicted and are uncertain, could include a negative impact on the availability of our key personnel, temporary closures of our facilities or the facilities of our business partners, customers, suppliers, third party service providers or other vendors, an increased risk of customer defaults or delays in payments or purchasing decisions, and the interruption of domestic and global supply chains, distribution channels, liquidity and capital or financial markets. As COVID-19 continues to spread, we have and may continue to experience disruptions that could severely impact our business. As such, the results for the three and nine months ended September 30, 2020 may not be indicative of results for the full year. Recently Issued Accounting Standards Accounting pronouncements adopted In August 2018, the FASB issued new accounting guidance that clarifies and aligns the accounting for implementation costs for hosting arrangements with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The Company adopted this new accounting guidance on January 1, 2020. The adoption of this new accounting guidance did not have a material effect on the Company’s consolidated financial statements. In August 2018, the FASB issued new accounting guidance that modifies the disclosure requirements in Topic 820, Fair Value Measurement, by removing certain disclosure requirements related to the fair value hierarchy, modifying existing disclosure requirements related to measurement uncertainty and adding new disclosure requirements, such as disclosing the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period and disclosing the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. This new accounting guidance also modifies the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans. The Company adopted this new accounting guidance on January 1, 2020. The adoption of this new accounting guidance did not have a material effect on the Company’s consolidated financial statements. In January 2017, the FASB issued new accounting guidance that simplifies the measurement of goodwill by eliminating the step two impairment test. Step two measures a goodwill impairment loss by comparing the implied fair value of goodwill with the carrying amount of that goodwill. The new guidance requires a comparison of the Company’s fair value of a reporting unit with the carrying amount and the Company is required to recognize an impairment charge for the amount by which the carrying amount exceeds the fair value. The Company adopted this new accounting guidance on January 1, 2020. The adoption of this new accounting guidance did not have a material effect on the Company’s consolidated financial statements. In June 2016, the FASB issued a new accounting standard intended to provide financial statement users with more decision-useful information about expected credit losses and other commitments to extend credit held by the reporting entity. The standard replaces the incurred loss impairment methodology in current GAAP with one that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The Company adopted this new accounting guidance on January 1, 2020. The adoption of this guidance did not have a material effect on the Company’s consolidated financial statements. This is based on factors including the Company's assessment of historical losses, client's creditworthiness and the fact that the Company's trade receivables are short term in duration. Accounting pronouncements being evaluated In March 2020, the FASB issued new accounting guidance that provides optional expedients and exceptions for applying U.S. GAAP to contract modifications and hedging relationships, subject to meeting certain criteria, that reference LIBOR or another rate that is expected to be discontinued. The new accounting guidance is effective for the Company as of March 12, 2020 through December 31, 2022. The Company is currently evaluating the impact of this new accounting guidance on its credit arrangements and derivatives that reference LIBOR. The Company does not expect the new accounting guidance to have a material effect on the Company’s consolidated financial statements. In January 2020, the FASB issued new accounting guidance that states any equity security transitioning from the alternative method of accounting to the equity method, or vice versa, due to an observable transaction, will be remeasured immediately before the transition. In addition, the new accounting guidance clarifies the accounting for certain non-derivative forward contracts or purchased call options to acquire equity securities stating such instruments will be measured using the fair value principles before settlement or exercise. The new accounting guidance will be effective for the Company on January 1, 2021 on a prospective basis. Early adoption is permitted. The Company is currently evaluating the impact of this new accounting guidance on its consolidated financial statements. In December 2019, the FASB issued new accounting guidance to clarify and simplify the accounting for income taxes. Changes under the new guidance includes eliminating certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new accounting guidance will be effective for the Company on January 1, 2021. Early adoption is permitted. The Company is currently evaluating the impact of this new accounting guidance on its consolidated financial statements.

Revenues by Geography, Concentr

Revenues by Geography, Concentration of Credit Risk and Remaining Performance Obligations	9 Months Ended
	Sep. 30, 2020
Revenue from Contract with Customer [Abstract]
Revenues by Geography, Concentration of Credit Risk and Remaining Performance Obligations	Revenues by Geography, Concentration of Credit Risk and Remaining Performance Obligations The following tables represent revenues by geographic region and reportable segment for the three and nine months ended September 30, 2020 and 2019: Three Months Ended September 30, 2020 (in millions) Technology & Analytics Solutions Research & Development Solutions Contract Sales & Medical Solutions Total Revenues: Americas $ 599 $ 628 $ 76 $ 1,303 Europe and Africa 457 411 44 912 Asia-Pacific 151 361 59 571 Total revenues $ 1,207 $ 1,400 $ 179 $ 2,786 Three Months Ended September 30, 2019 (in millions) Technology & Analytics Solutions Research & Development Solutions Contract Sales & Medical Solutions Total Revenues: Americas $ 580 $ 726 $ 104 $ 1,410 Europe and Africa 369 394 48 811 Asia-Pacific 146 346 56 548 Total revenues $ 1,095 $ 1,466 $ 208 $ 2,769 Nine Months Ended September 30, 2020 (in millions) Technology & Analytics Solutions Research & Development Solutions Contract Sales & Medical Solutions Total Revenues: Americas $ 1,747 $ 1,826 $ 247 $ 3,820 Europe and Africa 1,254 1,214 134 2,602 Asia-Pacific 432 1,036 171 1,639 Total revenues $ 3,433 $ 4,076 $ 552 $ 8,061 Nine Months Ended September 30, 2019 (in millions) Technology & Research & Contract Sales & Total Revenues: Americas $ 1,722 $ 2,009 $ 298 $ 4,029 Europe and Africa 1,128 1,298 148 2,574 Asia-Pacific 422 1,010 158 1,590 Total revenues $ 3,272 $ 4,317 $ 604 $ 8,193 No customer accounted for 10% or more of consolidated revenues for the three and nine months ended September 30, 2020 or 2019. Transaction Price Allocated to the Remaining Performance Obligations

Trade Accounts Receivable, Unbi

Trade Accounts Receivable, Unbilled Services and Unearned Income	9 Months Ended
	Sep. 30, 2020
Receivables [Abstract]
Trade Accounts Receivable, Unbilled Services and Unearned Income	Trade Accounts Receivable, Unbilled Services and Unearned Income Trade accounts receivables and unbilled services consist of the following: (in millions) September 30, 2020 December 31, 2019 Trade accounts receivable: Billed $ 1,152 $ 1,312 Unbilled services 1,292 1,286 Trade accounts receivable and unbilled services 2,444 2,598 Allowance for doubtful accounts (30) (16) Trade accounts receivable and unbilled services, net $ 2,414 $ 2,582 Unbilled services and unearned income were as follows: (in millions) September 30, 2020 December 31, 2019 Change Unbilled services $ 1,292 $ 1,286 $ 6 Unearned income (1,188) (1,014) (174) Net balance $ 104 $ 272 $ (168) Unbilled services, which is comprised of approximately 60% of unbilled receivables and 40% of contract assets as of September 30, 2020, increased by $6 million as compared to December 31, 2019. Contract assets are unbilled services for which invoicing is based on the timing of certain milestones related to service contracts for clinical research whereas unbilled receivables are billable upon the passage of time. Unearned income increased by $174 million over the same period resulting in a decrease of $168 million in the net balance of unbilled services and unearned income between December 31, 2019 and September 30, 2020. The change in the net balance is driven by the difference in timing of revenue recognition in accordance with ASC 606, Revenue from Contracts with Customers, related to the Company’s Research & Development Solutions contracts (which is based on the percentage of costs incurred) versus the timing of invoicing, which is based on certain milestones.

Leases

Leases	9 Months Ended
	Sep. 30, 2020
Leases [Abstract]
Leases	Leases The Company has operating leases for corporate offices, datacenters, motor vehicles and certain equipment, many of which contain renewal and escalation clauses. These operating leases expire at various dates through 2029 with options to cancel certain leases at various intervals. The Company also has finance leases for office and lab spaces that expire in 2044. Based on the timing of payments on the finance leases the cash flow impact is not material for the three and nine months ended September 30, 2020. In determining the lease term at lease commencement, the Company includes the noncancellable term and the periods which the Company deems it is reasonably certain to exercise or not to exercise a renewal or cancellation option. The components of lease expense were as follows: (in millions) Classification Three Months Ended September 30, 2020 Three Months Ended September 30, 2019 Operating lease cost (1) Selling, general and administrative expenses $ 49 $ 48 Finance lease cost (1) Depreciation and amortization, and Interest expense 3 — Total lease cost $ 52 $ 48 (in millions) Classification Nine Months Ended September 30, 2020 Nine Months Ended September 30, 2019 Operating lease cost (1) Selling, general and administrative expenses $ 151 $ 143 Finance lease cost (1) Depreciation and amortization, and Interest expense 4 — Total lease cost $ 155 $ 143 (1) Includes variable lease costs, which are immaterial. Other information related to leases was as follows: (in millions) Nine Months Ended September 30, 2020 Nine Months Ended September 30, 2019 Supplemental Cash Flow: Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 147 $ 147 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 92 $ 62 Finance leases $ 119 $ — Weighted Average Remaining Lease Term: Operating leases 4.65 years 4.90 years Finance leases 24.25 years — Weighted Average Discount Rate: Operating leases 4.04 % 4.26 % Finance leases 3.18 % — Future minimum lease payments under non-cancellable leases as of September 30, 2020 were as follows: (in millions) Operating Leases Finance Leases Remainder of 2020 $ 44 $ — 2021 153 — 2022 128 6 2023 100 6 2024 70 6 2025 56 6 Thereafter 44 159 Total future minimum lease payments 595 183 Less imputed interest (54) (63) Total $ 541 $ 120 Reported as of September 30, 2020: Other current liabilities $ 154 $ — Operating lease liabilities 387 — Other liabilities — 120 Total $ 541 $ 120

Goodwill

Goodwill	9 Months Ended
	Sep. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	Goodwill The following is a summary of goodwill by reportable segment for the nine months ended September 30, 2020: (in millions) Technology & Analytics Solutions Research & Development Solutions Contract Sales & Medical Solutions Consolidated Balance as of December 31, 2019 $ 10,374 $ 1,646 $ 139 $ 12,159 Business combinations 84 — — 84 Impact of foreign currency fluctuations and other 155 (39) 4 120 Balance as of September 30, 2020 $ 10,613 $ 1,607 $ 143 $ 12,363

Derivatives

Derivatives	9 Months Ended
	Sep. 30, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives	Derivatives The fair values of the Company’s derivative instruments and the line items on the accompanying condensed consolidated balance sheets to which they were recorded are summarized in the following table: (in millions) Balance Sheet Classification September 30, 2020 December 31, 2019 Assets Liabilities Notional Assets Liabilities Notional Derivatives designated as hedging instruments: Foreign exchange forward contracts Other current assets and liabilities $ 1 $ 1 $ 93 $ 4 $ — $ 148 Interest rate swaps Other assets and liabilities — 59 1,800 — 27 875 Derivatives not designated as hedging instruments: Interest rate swaps Other liabilities — 1 340 — 3 325 Total derivatives $ 1 $ 61 $ 4 $ 30 The effect of the Company’s cash flow hedging instruments on other comprehensive income is summarized in the following table: Three Months Ended September 30, Nine Months Ended September 30, (in millions) 2020 2019 2020 2019 Foreign exchange forward contracts $ 2 $ (1) $ (4) $ (5) Interest rate derivatives 1 (3) (32) (27) Total $ 3 $ (4) $ (36) $ (32) The amount of foreign exchange losses related to the net investment hedge included in the cumulative translation adjustment component of accumulated other comprehensive loss (“AOCI”) for the nine months ended September 30, 2020 was $273 million.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The Company records certain assets and liabilities at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A three-level fair value hierarchy that prioritizes the inputs used to measure fair value is described below. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: • Level 1 — Quoted prices in active markets for identical assets or liabilities. • Level 2 — Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data. • Level 3 — Unobservable inputs that are supported by little or no market activity. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. The carrying values of cash, cash equivalents, accounts receivable and accounts payable approximated their fair values at September 30, 2020 and December 31, 2019 due to their short-term nature. At September 30, 2020 and December 31, 2019, the fair value of total debt approximated $12,443 million and $11,925 million, respectively, as determined under Level 1 and Level 2 measurements for these financial instruments. Recurring Fair Value Measurements The following table summarizes the fair value of the Company’s financial assets and liabilities that are measured and reported at fair value on a recurring basis as of September 30, 2020: (in millions) Level 1 Level 2 Level 3 Total Assets: Marketable securities 105 $ — $ — $ 105 Derivatives — $ 1 — 1 Total $ 105 $ 1 $ — $ 106 Liabilities: Derivatives $ — $ 61 $ — $ 61 Contingent consideration — — 108 108 Total $ — $ 61 $ 108 $ 169 Below is a summary of the valuation techniques used in determining fair value: Marketable securities — The Company values trading and available-for-sale securities using the quoted market value of the securities held. Derivatives — Derivatives consist of foreign exchange contracts and interest rate swaps. The fair value of foreign exchange contracts is based on observable market inputs of spot and forward rates or using other observable inputs. The fair value of the interest rate swaps is the estimated amount that the Company would receive or pay to terminate such agreements, taking into account market interest rates and the remaining time to maturities or using market inputs with mid-market pricing as a practical expedient for bid-ask spread. Contingent consideration — The Company values contingent consideration related to business combinations using a weighted probability calculation of potential payment scenarios discounted at rates reflective of the risks associated with the expected future cash flows. Key assumptions used to estimate the fair value of contingent consideration include various financial metrics (revenue performance targets and operating forecasts) and the probability of achieving the specific targets. The following table summarizes the changes in Level 3 financial assets and liabilities measured on a recurring basis for the nine months ended September 30: Contingent Consideration (in millions) 2020 2019 Balance as of January 1 $ 113 $ 123 Business combinations 32 41 Contingent consideration paid (22) (44) Revaluations included in earnings and foreign currency translation adjustments (15) (7) Balance as of September 30 $ 108 $ 113 The Company used the following key assumptions when estimating the fair value of contingent considerations: Unobservable Input Weighted average probability of target achievement Range of potential payment Revenue target 89% 0%-100% EBITDA target 96% 0%-100% Operational target 95% 0%-100% The current portion of contingent consideration is included within accrued expenses and the long-term portion is included within other liabilities on the accompanying condensed consolidated balance sheets. Revaluations of the contingent consideration are recognized in other expense (income), net on the accompanying condensed consolidated statements of income. A change in significant unobservable inputs above could result in a significantly higher or lower fair value measurement of contingent consideration.

Credit Arrangements

Credit Arrangements	9 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
Credit Arrangements	Credit Arrangements The following is a summary of the Company’s revolving credit facilities at September 30, 2020: Facility Interest Rates $1,500 million (revolving credit facility) LIBOR in the relevant currency borrowed plus a margin of 1.50% at September 30, 2020 $25 million (receivables financing facility) LIBOR Market Index Rate (0.15% at September 30, 2020) plus 0.90% £10 million (approximately $13 million) (general banking facility) Bank’s base rate of 0.10% at September 30, 2020 plus 1% The following table summarizes the Company’s debt at the dates indicated: (in millions) September 30, 2020 December 31, 2019 Senior Secured Credit Facilities: Term A Loan due 2023—U.S. Dollar LIBOR at average floating rates of 1.72% $ 739 $ 770 Term A Loan due 2023—U.S. Dollar LIBOR at average floating rates of 2.75% 778 — Term A Loan due 2023—Euro LIBOR at average floating rates of 1.50% 388 387 Term B Loan due 2024—U.S. Dollar LIBOR at average floating rates of 1.90% 535 535 Term B Loan due 2024—Euro LIBOR at average floating rates of 2.00% 1,354 1,306 Term B Loan due 2025—U.S. Dollar LIBOR at average floating rates of 1.90% 728 733 Term B Loan due 2025—U.S. Dollar LIBOR at average floating rates of 1.97% 929 936 Term B Loan due 2025—Euro LIBOR at average floating rates of 2.00% 668 644 Revolving Credit Facility due 2023: U.S. Dollar denominated borrowings—U.S. Dollar LIBOR at average floating rates of 1.65% — 154 Japanese Yen denominated borrowings—Japanese Yen LIBOR at average floating rates of 1.50% — 212 5.0% Senior Notes due 2027—U.S. Dollar denominated 1,100 1,100 5.0% Senior Notes due 2026—U.S. Dollar denominated 1,050 1,050 2.875% Senior Notes due 2025—Euro denominated 492 471 3.25% Senior Notes due 2025—Euro denominated 1,671 1,598 3.5% Senior Notes due 2024—Euro denominated — 701 2.25% Senior Notes due 2028—Euro denominated 844 808 2.875% Senior Notes due 2028—Euro denominated 834 — Receivables financing facility due 2022—U.S. Dollar LIBOR at average floating rates of 1.05% 300 300 Principal amount of debt 12,410 11,705 Less: unamortized discount and debt issuance costs (71) (60) Less: current portion (144) (100) Long-term debt $ 12,195 $ 11,545 Contractual maturities of long-term debt are as follows at September 30, 2020: (in millions) Remainder of 2020 36 2021 146 2022 446 2023 1,699 2024 1,867 Thereafter 8,216 12,410 At September 30, 2020, there were bank guarantees totaling approximately £0.9 million (approximately $1.1 million) issued against the availability of the general banking facility. Senior Secured Credit Facilities At September 30, 2020, the Company’s Fourth Amended and Restated Credit Agreement, as amended (the “Credit Agreement”) provided financing through several senior secured credit facilities (collectively, the “senior secured credit facilities”) of up to approximately $7.6 billion, which consisted of $6.1 billion principal amounts of debt outstanding (as detailed in the table above), $1.5 billion of available borrowing capacity on the revolving credit facility and standby letters of credit. On March 11, 2020, the Company entered into Amendment No. 7 to the Credit Agreement to borrow $900 million in additional U.S. Dollar denominated term A loans due 2023 (the “TLA-2 Loans”) and, on March 30, 2020, entered into Amendment No. 8 to the Credit Agreement to amend certain terms of the TLA-2 Loans. The TLA-2 Loans bear interest based on the U.S. Dollar LIBOR plus a margin ranging from 1.50% to 2.25%, with a U.S. Dollar LIBOR floor of 1.00% per annum. The proceeds from the TLA-2 Loans were used to repay outstanding revolving credit loans under the Company's senior secured credit facilities. On March 30, 2020, the Company prepaid $100 million of the TLA-2 loans. Senior Notes On June 24, 2020, IQVIA Inc. (the “Issuer”), a wholly owned subsidiary of the Company, completed the issuance and sale of €711,000,000 in gross proceeds of the Issuer’s 2.875% senior notes due 2028 (the “2.875% Notes”). The 2.875% Notes were issued pursuant to an Indenture, dated June 24, 2020, among the Issuer, U.S. Bank National Association, as trustee of the Notes, and certain subsidiaries of the Issuer as guarantors. The 2.875% Notes are unsecured obligations of the Issuer, will mature on June 15, 2028 and bear interest at the rate of 2.875% per year, with interest payable semiannually on June 15 and December 15 of each year, beginning on December 15, 2020. The Issuer may redeem the 2.875% Notes prior to their final stated maturity, subject to a customary make-whole premium, at any time prior to June 15, 2023 (subject to a customary “equity claw” redemption right) and thereafter subject to a redemption premium declining from 1.438% to 0.000%. The proceeds from the 2.875% Notes offering were used to redeem all of the Issuer’s outstanding 3.500% senior notes due 2024 (the “3.500% Notes”), including the payment of premiums in respect thereof, to repay a portion of the existing borrowings under the Issuer’s revolving credit facility and to pay fees and expenses related to the offering. The Issuer’s obligations with respect to the 3.500% Notes were discharged on the same day as the Issuer completed the issuance of the 3.500% Notes, and the 3.500% Notes were redeemed on July 9, 2020. Restrictive Covenants The Company’s debt agreements provide for certain covenants and events of default customary for similar instruments, including a covenant not to exceed a specified ratio of consolidated senior secured net indebtedness to Consolidated EBITDA, as defined in the senior secured credit facility agreement and a covenant to maintain a specified minimum interest coverage ratio. If an event of default occurs under any of the Company’s or the Company’s subsidiaries’ financing arrangements, the creditors under such financing arrangements will be entitled to take various actions, including the acceleration of amounts due under such arrangements, and in the case of the lenders under the revolving credit facility and term loans, other actions permitted to be taken by a secured creditor. The Company’s long-term debt arrangements contain other usual and customary restrictive covenants that, among other things, place limitations on the Company’s ability to declare dividends. At September 30, 2020, the Company was in compliance with the financial covenants under its debt agreements in all material respects and does not have material uncertainty about ongoing ability to meet the covenants of the Company’s credit arrangements.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2020
Equity [Abstract]
Stockholders' Equity	Stockholders’ Equity Preferred Stock The Company is authorized to issue 1.0 million shares of preferred stock, $0.01 per share par value. No shares of preferred stock were issued or outstanding as of September 30, 2020 or December 31, 2019. Equity Repurchase Program During the nine months ended September 30, 2020, the Company repurchased 2,106,403 shares of its common stock for approximately $321.4 million under the Repurchase Program. These amounts include 1,000,000 shares of our common stock repurchased from certain of the Company’s stockholders (the “Selling Stockholders”) in a private transaction for an aggregate purchase price of approximately $164.3 million. As of September 30, 2020, the Company has remaining authorization to repurchase up to approximately $1.0 billion of its common stock under the Repurchase Program. In addition, from time to time, the Company has repurchased and may continue to repurchase common stock through private or other transactions outside of the Repurchase Program.

Restructuring

Restructuring	9 Months Ended
	Sep. 30, 2020
Restructuring and Related Activities [Abstract]
Restructuring	Restructuring The Company has continued to take restructuring actions in 2020 to align its resources and reduce overcapacity to adapt to changing market conditions and integrate acquisitions. These actions include consolidating functional activities, eliminating redundant positions, and aligning resources with customer requirements. These restructuring actions are expected to continue into 2021. The following amounts were recorded for the restructuring plans: (in millions) Severance and Related Costs Facility Exit Costs Total Balance at December 31, 2019 $ 64 $ 3 $ 67 Expense, net of reversals 50 — 50 Payments (51) (1) (52) Foreign currency translation and other — — — Balance at September 30, 2020 $ 63 $ 2 $ 65 Restructuring costs are not allocated to the Company’s reportable segments as they are not part of the segment performance measures regularly reviewed by management. The Company expects that the majority of the restructuring accruals at September 30, 2020 will be paid in 2020 and 2021.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2020
Income Tax Disclosure [Abstract]
Income Taxes	Income TaxesThe effective income tax rate was (2.9)% and (1.4)% in the third quarter of 2020 and 2019, respectively, and 5.0% and 18.8% in the first nine months of 2020 and 2019, respectively. In the third quarter 2020, the U.S. Treasury Department issued final regulations regarding Foreign Derived Intangible Income (“FDII”) and Global Intangible Low-Taxed Income (“GILTI”). The Company has determined it will elect the GILTI high tax exception as allowed by the final regulations and will amend its 2018 and 2019 US Federal consolidated income tax returns resulting in a favorable impact of $24 million. The Company recorded this impact in the third quarter of 2020. The effective income tax rate in the third quarter and first nine months of 2020 and 2019 was also favorably impacted as a result of excess tax benefits recognized upon settlement of share-based compensation awards. For the third quarter of 2020 and 2019 this impact was $9 million and $3 million, respectively, and for the first nine months of 2020 and 2019 this impact was $35 million and $20 million, respectively. Additionally, the effective income tax rate in the first nine months of 2020 was unfavorably impacted by a $10 million discrete tax expense related to change in the measurement of the U.S. tax on undistributed foreign earnings.In the first nine months of 2019 the U.S. Treasury Department issued final regulations on the transition tax and proposed regulations on FDII. While the final regulations related to the transition tax did not have a material impact on the Company, the proposed guidance on FDII had an unfavorable impact. Although the proposed guidance for FDII was not authoritative and subject to change in the regulatory review process, the Company reversed a portion of the tax benefit related to 2018 and recorded a tax expense of $20 million for this impact in the first nine months of 2019.

Comprehensive Income (Loss)

Comprehensive Income (Loss)	9 Months Ended
	Sep. 30, 2020
Equity [Abstract]
Comprehensive Income (Loss)	Comprehensive Income (Loss) Below is a summary of the components of AOCI: (in millions) Foreign Currency Translation Derivative Instruments Defined Benefit Plans Income Taxes Total Balance at December 31, 2019 $ (430) $ (21) $ (16) $ 156 $ (311) Other comprehensive income (loss) before reclassifications (62) (44) — 94 (12) Reclassification adjustments — 8 — (2) 6 Balance at September 30, 2020 $ (492) $ (57) $ (16) $ 248 $ (317) Below is a summary of the adjustments for (gains) losses reclassified from AOCI into the condensed consolidated statements of income and the affected financial statement line item: (in millions) Affected Financial Statement Line Item Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Derivative instruments: Foreign exchange forward contracts Revenues $ 4 $ 2 $ 9 $ 3 Foreign exchange forward contracts Other expense (income), net (1) — (1) (6) Total before income taxes 3 2 8 (3) Income tax (benefit) expense 1 — 2 (1) Total net of income taxes $ 2 $ 2 $ 6 $ (2)

Segments

Segments	9 Months Ended
	Sep. 30, 2020
Segment Reporting [Abstract]
Segments	Segments The following table presents the Company’s operations by reportable segment. The Company is managed through three reportable segments, Technology & Analytics Solutions, Research & Development Solutions and Contract Sales & Medical Solutions. Technology & Analytics Solutions provides mission-critical information, technology solutions and real-world insights and services to the Company’s life sciences customers. Research & Development Solutions, which primarily serves biopharmaceutical customers, provides outsourced clinical research and clinical trial related services. Contract Sales & Medical Solutions provides health care provider (including contract sales) and patient engagement services to both biopharmaceutical customers and the broader healthcare market. Certain costs are not allocated to the Company’s segments and are reported as general corporate and unallocated expenses. These costs primarily consist of stock-based compensation and expenses related to integration activities and acquisitions. The Company also does not allocate depreciation and amortization or impairment charges to its segments. Asset information by segment is not presented, as this measure is not used by the chief operating decision maker to assess the Company’s performance. The Company’s reportable segment information is presented below: Three Months Ended September 30, Nine Months Ended September 30, (in millions) 2020 2019 2020 2019 Revenues Technology & Analytics Solutions $ 1,207 $ 1,095 $ 3,433 $ 3,272 Research & Development Solutions 1,400 1,466 4,076 4,317 Contract Sales & Medical Solutions 179 208 552 604 Total revenues 2,786 2,769 8,061 8,193 Costs of revenue, exclusive of depreciation and amortization Technology & Analytics Solutions 727 667 2,048 1,956 Research & Development Solutions 925 1,007 2,811 2,924 Contract Sales & Medical Solutions 148 178 469 519 Total costs of revenue 1,800 1,852 5,328 5,399 Selling, general and administrative expenses Technology & Analytics Solutions 188 167 549 539 Research & Development Solutions 184 172 544 529 Contract Sales & Medical Solutions 14 15 44 45 General corporate and unallocated 74 41 161 137 Total selling, general and administrative expenses 460 395 1,298 1,250 Segment profit Technology & Analytics Solutions 292 261 836 777 Research & Development Solutions 291 287 721 864 Contract Sales & Medical Solutions 17 15 39 40 Total segment profit 600 563 1,596 1,681 General corporate and unallocated (74) (41) (161) (137) Depreciation and amortization (319) (299) (943) (888) Restructuring costs (20) (19) (50) (45) Total income from operations $ 187 $ 204 $ 442 $ 611

Earnings Per Share

Earnings Per Share	9 Months Ended
	Sep. 30, 2020
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share The following table presents the weighted average number of outstanding stock-based awards not included in the computation of diluted earnings per share because they are subject to performance conditions or the effect of including such stock-based awards in the computation would be anti-dilutive: Three Months Ended September 30, Nine Months Ended September 30, (in millions) 2020 2019 2020 2019 Shares subject to performance conditions 1.1 1.3 1.2 1.3 Shares subject to anti-dilutive stock-based awards 1.1 0.4 1.3 0.7 Total shares excluded from diluted earnings per share 2.2 1.7 2.5 2.0 The vesting of performance awards is contingent upon the achievement of certain performance targets. The performance awards are not included in diluted earnings per share until the performance targets have been met. Stock-based awards will have a dilutive effect under the treasury method when the respective period’s average market value of the Company’s common stock exceeds the exercise proceeds.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Unaudited Interim Financial Information	Unaudited Interim Financial Information The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair statement of the Company’s financial condition and results of operations have been included. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the year ending December 31, 2020. As such, the information included in this Quarterly Report on Form 10-Q should be read in conjunction with the Company’s audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019. The balance sheet at December 31, 2019 has been derived from the audited consolidated financial statements of the Company but does not include all the disclosures required by GAAP. Additionally, t he outbreak of the novel coronavirus, or COVID-19, and the various governmental, industry and consumer actions related thereto, could have a material and adverse effect on our business, financial condition and results of operations. These effects, which largely depend on future developments that cannot be accurately predicted and are uncertain, could include a negative impact on the availability of our key personnel, temporary closures of our facilities or the facilities of our business partners, customers, suppliers, third party service providers or other vendors, an increased risk of customer defaults or delays in payments or purchasing decisions, and the interruption of domestic and global supply chains, distribution channels, liquidity and capital or financial markets. As COVID-19 continues to spread, we have and may continue to experience disruptions that could severely impact our business. As such, the results for the three and nine months ended September 30, 2020 may not be indicative of results for the full year.
Recently Issued Accounting Standards	Recently Issued Accounting Standards Accounting pronouncements adopted In August 2018, the FASB issued new accounting guidance that clarifies and aligns the accounting for implementation costs for hosting arrangements with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The Company adopted this new accounting guidance on January 1, 2020. The adoption of this new accounting guidance did not have a material effect on the Company’s consolidated financial statements. In August 2018, the FASB issued new accounting guidance that modifies the disclosure requirements in Topic 820, Fair Value Measurement, by removing certain disclosure requirements related to the fair value hierarchy, modifying existing disclosure requirements related to measurement uncertainty and adding new disclosure requirements, such as disclosing the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period and disclosing the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. This new accounting guidance also modifies the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans. The Company adopted this new accounting guidance on January 1, 2020. The adoption of this new accounting guidance did not have a material effect on the Company’s consolidated financial statements. In January 2017, the FASB issued new accounting guidance that simplifies the measurement of goodwill by eliminating the step two impairment test. Step two measures a goodwill impairment loss by comparing the implied fair value of goodwill with the carrying amount of that goodwill. The new guidance requires a comparison of the Company’s fair value of a reporting unit with the carrying amount and the Company is required to recognize an impairment charge for the amount by which the carrying amount exceeds the fair value. The Company adopted this new accounting guidance on January 1, 2020. The adoption of this new accounting guidance did not have a material effect on the Company’s consolidated financial statements. In June 2016, the FASB issued a new accounting standard intended to provide financial statement users with more decision-useful information about expected credit losses and other commitments to extend credit held by the reporting entity. The standard replaces the incurred loss impairment methodology in current GAAP with one that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The Company adopted this new accounting guidance on January 1, 2020. The adoption of this guidance did not have a material effect on the Company’s consolidated financial statements. This is based on factors including the Company's assessment of historical losses, client's creditworthiness and the fact that the Company's trade receivables are short term in duration. Accounting pronouncements being evaluated In March 2020, the FASB issued new accounting guidance that provides optional expedients and exceptions for applying U.S. GAAP to contract modifications and hedging relationships, subject to meeting certain criteria, that reference LIBOR or another rate that is expected to be discontinued. The new accounting guidance is effective for the Company as of March 12, 2020 through December 31, 2022. The Company is currently evaluating the impact of this new accounting guidance on its credit arrangements and derivatives that reference LIBOR. The Company does not expect the new accounting guidance to have a material effect on the Company’s consolidated financial statements. In January 2020, the FASB issued new accounting guidance that states any equity security transitioning from the alternative method of accounting to the equity method, or vice versa, due to an observable transaction, will be remeasured immediately before the transition. In addition, the new accounting guidance clarifies the accounting for certain non-derivative forward contracts or purchased call options to acquire equity securities stating such instruments will be measured using the fair value principles before settlement or exercise. The new accounting guidance will be effective for the Company on January 1, 2021 on a prospective basis. Early adoption is permitted. The Company is currently evaluating the impact of this new accounting guidance on its consolidated financial statements. In December 2019, the FASB issued new accounting guidance to clarify and simplify the accounting for income taxes. Changes under the new guidance includes eliminating certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new accounting guidance will be effective for the Company on January 1, 2021. Early adoption is permitted. The Company is currently evaluating the impact of this new accounting guidance on its consolidated financial statements.

Revenues by Geography, Concen_2

Revenues by Geography, Concentration of Credit Risk and Remaining Performance Obligations (Tables)	9 Months Ended
	Sep. 30, 2020
Revenue from Contract with Customer [Abstract]
Summary of Revenues by Geographic Region and Reportable Segment	The following tables represent revenues by geographic region and reportable segment for the three and nine months ended September 30, 2020 and 2019: Three Months Ended September 30, 2020 (in millions) Technology & Analytics Solutions Research & Development Solutions Contract Sales & Medical Solutions Total Revenues: Americas $ 599 $ 628 $ 76 $ 1,303 Europe and Africa 457 411 44 912 Asia-Pacific 151 361 59 571 Total revenues $ 1,207 $ 1,400 $ 179 $ 2,786 Three Months Ended September 30, 2019 (in millions) Technology & Analytics Solutions Research & Development Solutions Contract Sales & Medical Solutions Total Revenues: Americas $ 580 $ 726 $ 104 $ 1,410 Europe and Africa 369 394 48 811 Asia-Pacific 146 346 56 548 Total revenues $ 1,095 $ 1,466 $ 208 $ 2,769 Nine Months Ended September 30, 2020 (in millions) Technology & Analytics Solutions Research & Development Solutions Contract Sales & Medical Solutions Total Revenues: Americas $ 1,747 $ 1,826 $ 247 $ 3,820 Europe and Africa 1,254 1,214 134 2,602 Asia-Pacific 432 1,036 171 1,639 Total revenues $ 3,433 $ 4,076 $ 552 $ 8,061 Nine Months Ended September 30, 2019 (in millions) Technology & Research & Contract Sales & Total Revenues: Americas $ 1,722 $ 2,009 $ 298 $ 4,029 Europe and Africa 1,128 1,298 148 2,574 Asia-Pacific 422 1,010 158 1,590 Total revenues $ 3,272 $ 4,317 $ 604 $ 8,193

Trade Accounts Receivable, Un_2

Trade Accounts Receivable, Unbilled Services and Unearned Income (Tables)	9 Months Ended
	Sep. 30, 2020
Receivables [Abstract]
Schedule of Trade Accounts Receivable and Unbilled Services	Trade accounts receivables and unbilled services consist of the following: (in millions) September 30, 2020 December 31, 2019 Trade accounts receivable: Billed $ 1,152 $ 1,312 Unbilled services 1,292 1,286 Trade accounts receivable and unbilled services 2,444 2,598 Allowance for doubtful accounts (30) (16) Trade accounts receivable and unbilled services, net $ 2,414 $ 2,582
Schedule of Net Contract Assets (Liabilities)	Unbilled services and unearned income were as follows: (in millions) September 30, 2020 December 31, 2019 Change Unbilled services $ 1,292 $ 1,286 $ 6 Unearned income (1,188) (1,014) (174) Net balance $ 104 $ 272 $ (168)

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2020
Leases [Abstract]
Schedule of Components of Lease Expense	The components of lease expense were as follows: (in millions) Classification Three Months Ended September 30, 2020 Three Months Ended September 30, 2019 Operating lease cost (1) Selling, general and administrative expenses $ 49 $ 48 Finance lease cost (1) Depreciation and amortization, and Interest expense 3 — Total lease cost $ 52 $ 48 (in millions) Classification Nine Months Ended September 30, 2020 Nine Months Ended September 30, 2019 Operating lease cost (1) Selling, general and administrative expenses $ 151 $ 143 Finance lease cost (1) Depreciation and amortization, and Interest expense 4 — Total lease cost $ 155 $ 143 (1) Includes variable lease costs, which are immaterial.
Summary of Other Information Related to Leases	Other information related to leases was as follows: (in millions) Nine Months Ended September 30, 2020 Nine Months Ended September 30, 2019 Supplemental Cash Flow: Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 147 $ 147 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 92 $ 62 Finance leases $ 119 $ — Weighted Average Remaining Lease Term: Operating leases 4.65 years 4.90 years Finance leases 24.25 years — Weighted Average Discount Rate: Operating leases 4.04 % 4.26 % Finance leases 3.18 % —
Schedule of Future Minimum Lease Payments Under Non-cancellable Leases	Future minimum lease payments under non-cancellable leases as of September 30, 2020 were as follows: (in millions) Operating Leases Finance Leases Remainder of 2020 $ 44 $ — 2021 153 — 2022 128 6 2023 100 6 2024 70 6 2025 56 6 Thereafter 44 159 Total future minimum lease payments 595 183 Less imputed interest (54) (63) Total $ 541 $ 120 Reported as of September 30, 2020: Other current liabilities $ 154 $ — Operating lease liabilities 387 — Other liabilities — 120 Total $ 541 $ 120

Goodwill (Tables)

Goodwill (Tables)	9 Months Ended
	Sep. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Goodwill by Reportable Segment	The following is a summary of goodwill by reportable segment for the nine months ended September 30, 2020: (in millions) Technology & Analytics Solutions Research & Development Solutions Contract Sales & Medical Solutions Consolidated Balance as of December 31, 2019 $ 10,374 $ 1,646 $ 139 $ 12,159 Business combinations 84 — — 84 Impact of foreign currency fluctuations and other 155 (39) 4 120 Balance as of September 30, 2020 $ 10,613 $ 1,607 $ 143 $ 12,363

Derivatives (Tables)

Derivatives (Tables)	9 Months Ended
	Sep. 30, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Summary of Fair Values of Derivative Instruments Designated as Hedges	The fair values of the Company’s derivative instruments and the line items on the accompanying condensed consolidated balance sheets to which they were recorded are summarized in the following table: (in millions) Balance Sheet Classification September 30, 2020 December 31, 2019 Assets Liabilities Notional Assets Liabilities Notional Derivatives designated as hedging instruments: Foreign exchange forward contracts Other current assets and liabilities $ 1 $ 1 $ 93 $ 4 $ — $ 148 Interest rate swaps Other assets and liabilities — 59 1,800 — 27 875 Derivatives not designated as hedging instruments: Interest rate swaps Other liabilities — 1 340 — 3 325 Total derivatives $ 1 $ 61 $ 4 $ 30
Schedule of Effect of Cash Flow Hedging Instruments on Other Comprehensive (Loss) Income	The effect of the Company’s cash flow hedging instruments on other comprehensive income is summarized in the following table: Three Months Ended September 30, Nine Months Ended September 30, (in millions) 2020 2019 2020 2019 Foreign exchange forward contracts $ 2 $ (1) $ (4) $ (5) Interest rate derivatives 1 (3) (32) (27) Total $ 3 $ (4) $ (36) $ (32)

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2020
Fair Value Disclosures [Abstract]
Summary of Fair Value of Financial Assets and Liabilities Measured on Recurring Basis	The following table summarizes the fair value of the Company’s financial assets and liabilities that are measured and reported at fair value on a recurring basis as of September 30, 2020: (in millions) Level 1 Level 2 Level 3 Total Assets: Marketable securities 105 $ — $ — $ 105 Derivatives — $ 1 — 1 Total $ 105 $ 1 $ — $ 106 Liabilities: Derivatives $ — $ 61 $ — $ 61 Contingent consideration — — 108 108 Total $ — $ 61 $ 108 $ 169
Schedule of Changes in Level 3 Financial Assets and Liabilities Measured on Recurring Basis	The following table summarizes the changes in Level 3 financial assets and liabilities measured on a recurring basis for the nine months ended September 30: Contingent Consideration (in millions) 2020 2019 Balance as of January 1 $ 113 $ 123 Business combinations 32 41 Contingent consideration paid (22) (44) Revaluations included in earnings and foreign currency translation adjustments (15) (7) Balance as of September 30 $ 108 $ 113
Schedule of Fair Value Measurement Inputs and Valuation Techniques	The Company used the following key assumptions when estimating the fair value of contingent considerations: Unobservable Input Weighted average probability of target achievement Range of potential payment Revenue target 89% 0%-100% EBITDA target 96% 0%-100% Operational target 95% 0%-100%

Credit Arrangements (Tables)

Credit Arrangements (Tables)	9 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
Summary of Credit Facilities	The following is a summary of the Company’s revolving credit facilities at September 30, 2020: Facility Interest Rates $1,500 million (revolving credit facility) LIBOR in the relevant currency borrowed plus a margin of 1.50% at September 30, 2020 $25 million (receivables financing facility) LIBOR Market Index Rate (0.15% at September 30, 2020) plus 0.90% £10 million (approximately $13 million) (general banking facility) Bank’s base rate of 0.10% at September 30, 2020 plus 1%
Summary of Debt	The following table summarizes the Company’s debt at the dates indicated: (in millions) September 30, 2020 December 31, 2019 Senior Secured Credit Facilities: Term A Loan due 2023—U.S. Dollar LIBOR at average floating rates of 1.72% $ 739 $ 770 Term A Loan due 2023—U.S. Dollar LIBOR at average floating rates of 2.75% 778 — Term A Loan due 2023—Euro LIBOR at average floating rates of 1.50% 388 387 Term B Loan due 2024—U.S. Dollar LIBOR at average floating rates of 1.90% 535 535 Term B Loan due 2024—Euro LIBOR at average floating rates of 2.00% 1,354 1,306 Term B Loan due 2025—U.S. Dollar LIBOR at average floating rates of 1.90% 728 733 Term B Loan due 2025—U.S. Dollar LIBOR at average floating rates of 1.97% 929 936 Term B Loan due 2025—Euro LIBOR at average floating rates of 2.00% 668 644 Revolving Credit Facility due 2023: U.S. Dollar denominated borrowings—U.S. Dollar LIBOR at average floating rates of 1.65% — 154 Japanese Yen denominated borrowings—Japanese Yen LIBOR at average floating rates of 1.50% — 212 5.0% Senior Notes due 2027—U.S. Dollar denominated 1,100 1,100 5.0% Senior Notes due 2026—U.S. Dollar denominated 1,050 1,050 2.875% Senior Notes due 2025—Euro denominated 492 471 3.25% Senior Notes due 2025—Euro denominated 1,671 1,598 3.5% Senior Notes due 2024—Euro denominated — 701 2.25% Senior Notes due 2028—Euro denominated 844 808 2.875% Senior Notes due 2028—Euro denominated 834 — Receivables financing facility due 2022—U.S. Dollar LIBOR at average floating rates of 1.05% 300 300 Principal amount of debt 12,410 11,705 Less: unamortized discount and debt issuance costs (71) (60) Less: current portion (144) (100) Long-term debt $ 12,195 $ 11,545
Schedule of Contractual Maturities of Long-term Debt	Contractual maturities of long-term debt are as follows at September 30, 2020: (in millions) Remainder of 2020 36 2021 146 2022 446 2023 1,699 2024 1,867 Thereafter 8,216 12,410

Restructuring (Tables)

Restructuring (Tables)	9 Months Ended
	Sep. 30, 2020
Restructuring and Related Activities [Abstract]
Summary of Amounts Recorded for Restructuring Plans	The following amounts were recorded for the restructuring plans: (in millions) Severance and Related Costs Facility Exit Costs Total Balance at December 31, 2019 $ 64 $ 3 $ 67 Expense, net of reversals 50 — 50 Payments (51) (1) (52) Foreign currency translation and other — — — Balance at September 30, 2020 $ 63 $ 2 $ 65

Comprehensive Income (Loss) (Ta

Comprehensive Income (Loss) (Tables)	9 Months Ended
	Sep. 30, 2020
Equity [Abstract]
Summary of Components of AOCI	Below is a summary of the components of AOCI: (in millions) Foreign Currency Translation Derivative Instruments Defined Benefit Plans Income Taxes Total Balance at December 31, 2019 $ (430) $ (21) $ (16) $ 156 $ (311) Other comprehensive income (loss) before reclassifications (62) (44) — 94 (12) Reclassification adjustments — 8 — (2) 6 Balance at September 30, 2020 $ (492) $ (57) $ (16) $ 248 $ (317)
Summary of Adjustments for (Gains) Losses Reclassified from AOCI into Condensed Consolidated Statements of Income and Affected Financial Statement Line Item	Below is a summary of the adjustments for (gains) losses reclassified from AOCI into the condensed consolidated statements of income and the affected financial statement line item: (in millions) Affected Financial Statement Line Item Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Derivative instruments: Foreign exchange forward contracts Revenues $ 4 $ 2 $ 9 $ 3 Foreign exchange forward contracts Other expense (income), net (1) — (1) (6) Total before income taxes 3 2 8 (3) Income tax (benefit) expense 1 — 2 (1) Total net of income taxes $ 2 $ 2 $ 6 $ (2)

Segments (Tables)

Segments (Tables)	9 Months Ended
	Sep. 30, 2020
Segment Reporting [Abstract]
Reconciliation of Revenues and Income from Segments to Consolidated	Asset information by segment is not presented, as this measure is not used by the chief operating decision maker to assess the Company’s performance. The Company’s reportable segment information is presented below: Three Months Ended September 30, Nine Months Ended September 30, (in millions) 2020 2019 2020 2019 Revenues Technology & Analytics Solutions $ 1,207 $ 1,095 $ 3,433 $ 3,272 Research & Development Solutions 1,400 1,466 4,076 4,317 Contract Sales & Medical Solutions 179 208 552 604 Total revenues 2,786 2,769 8,061 8,193 Costs of revenue, exclusive of depreciation and amortization Technology & Analytics Solutions 727 667 2,048 1,956 Research & Development Solutions 925 1,007 2,811 2,924 Contract Sales & Medical Solutions 148 178 469 519 Total costs of revenue 1,800 1,852 5,328 5,399 Selling, general and administrative expenses Technology & Analytics Solutions 188 167 549 539 Research & Development Solutions 184 172 544 529 Contract Sales & Medical Solutions 14 15 44 45 General corporate and unallocated 74 41 161 137 Total selling, general and administrative expenses 460 395 1,298 1,250 Segment profit Technology & Analytics Solutions 292 261 836 777 Research & Development Solutions 291 287 721 864 Contract Sales & Medical Solutions 17 15 39 40 Total segment profit 600 563 1,596 1,681 General corporate and unallocated (74) (41) (161) (137) Depreciation and amortization (319) (299) (943) (888) Restructuring costs (20) (19) (50) (45) Total income from operations $ 187 $ 204 $ 442 $ 611

Earnings Per Share (Tables)

Earnings Per Share (Tables)	9 Months Ended
	Sep. 30, 2020
Earnings Per Share [Abstract]
Summary of Weighted-Average Outstanding Stock-Based Awards Excluded from Computation of Diluted Earnings Per Share	The following table presents the weighted average number of outstanding stock-based awards not included in the computation of diluted earnings per share because they are subject to performance conditions or the effect of including such stock-based awards in the computation would be anti-dilutive: Three Months Ended September 30, Nine Months Ended September 30, (in millions) 2020 2019 2020 2019 Shares subject to performance conditions 1.1 1.3 1.2 1.3 Shares subject to anti-dilutive stock-based awards 1.1 0.4 1.3 0.7 Total shares excluded from diluted earnings per share 2.2 1.7 2.5 2.0

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Detail) Employee in Thousands	Sep. 30, 2020EmployeeCountry
Summary Of Significant Accounting Policies [Line Items]
Number of employees | Employee	68
Minimum
Summary Of Significant Accounting Policies [Line Items]
Number of countries (more than) | Country	100

Revenues by Geography, Concen_3

Revenues by Geography, Concentration of Credit Risk and Remaining Performance Obligations - Summary of Revenues by Geographic Region and Reportable Segment (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Disaggregation of Revenue
Total revenues	$ 2,786	$ 2,769	$ 8,061	$ 8,193
Americas
Disaggregation of Revenue
Total revenues	1,303	1,410	3,820	4,029
Europe and Africa
Disaggregation of Revenue
Total revenues	912	811	2,602	2,574
Asia-Pacific
Disaggregation of Revenue
Total revenues	571	548	1,639	1,590
Technology & Analytics Solutions
Disaggregation of Revenue
Total revenues	1,207	1,095	3,433	3,272
Technology & Analytics Solutions | Americas
Disaggregation of Revenue
Total revenues	599	580	1,747	1,722
Technology & Analytics Solutions | Europe and Africa
Disaggregation of Revenue
Total revenues	457	369	1,254	1,128
Technology & Analytics Solutions | Asia-Pacific
Disaggregation of Revenue
Total revenues	151	146	432	422
Research & Development Solutions
Disaggregation of Revenue
Total revenues	1,400	1,466	4,076	4,317
Research & Development Solutions | Americas
Disaggregation of Revenue
Total revenues	628	726	1,826	2,009
Research & Development Solutions | Europe and Africa
Disaggregation of Revenue
Total revenues	411	394	1,214	1,298
Research & Development Solutions | Asia-Pacific
Disaggregation of Revenue
Total revenues	361	346	1,036	1,010
Contract Sales & Medical Solutions
Disaggregation of Revenue
Total revenues	179	208	552	604
Contract Sales & Medical Solutions | Americas
Disaggregation of Revenue
Total revenues	76	104	247	298
Contract Sales & Medical Solutions | Europe and Africa
Disaggregation of Revenue
Total revenues	44	48	134	148
Contract Sales & Medical Solutions | Asia-Pacific
Disaggregation of Revenue
Total revenues	$ 59	$ 56	$ 171	$ 158

Revenues by Geography, Concen_4

Revenues by Geography, Concentration of Credit Risk and Remaining Performance Obligations - Additional Information (Detail) $ in Billions	3 Months Ended		9 Months Ended
	Sep. 30, 2020USD ($)Customer	Sep. 30, 2019Customer	Sep. 30, 2020USD ($)Customer	Sep. 30, 2019Customer
Revenue from Contract with Customer [Abstract]
Number of customer accounting for ten percent or more of revenue | Customer	0	0	0	0
Revenue expected to be recognized in future from remaining performance obligations | $	$ 23.6		$ 23.6

Revenues by Geography, Concen_5

Revenues by Geography, Concentration of Credit Risk and Remaining Performance Obligations - Future Obligation Terms (Detail) - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-10-01	Sep. 30, 2020
Disaggregation of Revenue
Percentage of remaining performance obligations on which revenue is expected to be recognized (in percent)	30.00%
Unearned income recognition period	12 months

Trade Accounts Receivable, Un_3

Trade Accounts Receivable, Unbilled Services and Unearned Income - Trade Accounts Receivable and Unbilled Services (Detail) - USD ($) $ in Millions	Sep. 30, 2020	Dec. 31, 2019
Trade accounts receivable:
Billed	$ 1,152	$ 1,312
Unbilled services	1,292	1,286
Trade accounts receivable and unbilled services	2,444	2,598
Allowance for doubtful accounts	(30)	(16)
Trade accounts receivable and unbilled services, net	$ 2,414	$ 2,582

Trade Accounts Receivable, Un_4

Trade Accounts Receivable, Unbilled Services and Unearned Income - Schedule of Net Contract Assets (Liabilities) (Detail) $ in Millions	9 Months Ended
	Sep. 30, 2020USD ($)
Unbilled Contracts Receivables
Unbilled services, beginning balance	$ 1,286
Change	6
Unbilled services, ending balance	1,292
Unearned Income
Unearned income, beginning balance	(1,014)
Change	(174)
Unearned income, ending balance	(1,188)
Net balance, beginning balance	272
Change	(168)
Net, balance ending balance	$ 104

Trade Accounts Receivable, Un_5

Trade Accounts Receivable, Unbilled Services and Unearned Income - Additional Information (Detail) $ in Millions	9 Months Ended
	Sep. 30, 2020USD ($)
Receivables [Abstract]
Unbilled receivables (percentage)	60.00%
Contract assets (percentage)	40.00%
Increase in unbilled services	$ 6
Increase in unearned income	174
Net change in balance	$ (168)

Leases - Additional Information

Leases - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2020
Leases [Abstract]
Operating lease year of expiry	2029

Leases - Components of Lease Ex

Leases - Components of Lease Expense (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Lessee, Lease, Description
Total lease cost	$ 52	$ 48	$ 155	$ 143
Selling, general and administrative expenses
Lessee, Lease, Description
Operating lease cost	49	48	151	143
Depreciation and amortization, and Interest expense
Lessee, Lease, Description
Finance lease cost	$ 3	$ 0	$ 4	$ 0

Leases - Other Information Rela

Leases - Other Information Related to Leases (Detail) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 147	$ 147
Right-of-use assets obtained in exchange for lease obligations:
Operating leases	92	62
Finance leases	$ 119	$ 0
Weighted Average Remaining Lease Term:
Operating leases	4 years 7 months 24 days	4 years 10 months 24 days
Finance leases	24 years 3 months
Weighted Average Discount Rate:
Operating leases	4.04%	4.26%
Finance leases	3.18%

Leases - Future Minimum Lease P

Leases - Future Minimum Lease Payments Under Non-cancellable Leases (Detail) - USD ($) $ in Millions	Sep. 30, 2020	Dec. 31, 2019
Operating Leases
Remainder of 2020	$ 44
2021	153
2022	128
2023	100
2024	70
2025	56
Thereafter	44
Total future minimum lease payments	595
Less imputed interest	(54)
Total	541
Other current liabilities	154
Operating lease liabilities	387	$ 396
Total	541
Finance Leases
Remainder of 2020	0
2021	0
2022	6
2023	6
2024	6
2025	6
Thereafter	159
Total future minimum lease payments	183
Less imputed interest	(63)
Total	120
Other liabilities	120
Total	$ 120

Goodwill - Summary of Goodwill

Goodwill - Summary of Goodwill by Reportable Segment (Detail) $ in Millions	9 Months Ended
	Sep. 30, 2020USD ($)
Goodwill
Beginning balance	$ 12,159
Business combinations	84
Impact of foreign currency fluctuations and other	120
Ending balance	12,363
Technology & Analytics Solutions
Goodwill
Beginning balance	10,374
Business combinations	84
Impact of foreign currency fluctuations and other	155
Ending balance	10,613
Research & Development Solutions
Goodwill
Beginning balance	1,646
Business combinations	0
Impact of foreign currency fluctuations and other	(39)
Ending balance	1,607
Contract Sales & Medical Solutions
Goodwill
Beginning balance	139
Business combinations	0
Impact of foreign currency fluctuations and other	4
Ending balance	$ 143

Derivatives - Summary of Fair V

Derivatives - Summary of Fair Values of Derivative Instruments Designated as Hedges (Detail) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Derivatives, Fair Value
Assets	$ 1,000,000	$ 4,000,000
Liabilities	61,000,000	30,000,000
Derivatives designated as hedging instruments: | Other current assets and liabilities | Foreign exchange forward contracts
Derivatives, Fair Value
Assets	1,000,000	4,000,000
Liabilities	1,000,000	0
Notional	93,000,000	148,000,000
Derivatives designated as hedging instruments: | Other assets and liabilities | Interest rate swaps
Derivatives, Fair Value
Assets	0	0
Liabilities	59,000,000	27,000,000
Notional	1,800,000,000	875,000,000
Derivatives not designated as hedging instruments: | Other liabilities | Interest rate swaps
Derivatives, Fair Value
Assets	0	0
Liabilities	1,000,000	3,000,000
Notional	$ 340,000,000	$ 325,000,000

Derivatives - Effect of Cash Fl

Derivatives - Effect of Cash Flow Hedging Instruments on Other Comprehensive (Loss) Income (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Derivative Instruments and Hedging Activities Disclosures
Effect of cash flow hedging instruments on other comprehensive (loss) income	$ 3	$ (4)	$ (36)	$ (32)
Foreign exchange forward contracts
Derivative Instruments and Hedging Activities Disclosures
Effect of cash flow hedging instruments on other comprehensive (loss) income	2	(1)	(4)	(5)
Interest rate derivatives
Derivative Instruments and Hedging Activities Disclosures
Effect of cash flow hedging instruments on other comprehensive (loss) income	$ 1	$ (3)	$ (32)	$ (27)

Derivatives - Additional Inform

Derivatives - Additional Information (Detail) $ in Millions	Sep. 30, 2020USD ($)
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Foreign exchange loss related to net investment hedge	$ 273

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($) $ in Millions	Sep. 30, 2020	Dec. 31, 2019
Level 1 and Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Fair value of total debt	$ 12,443	$ 11,925

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value of Financial Assets and Liabilities Measured on Recurring Basis (Detail) - USD ($) $ in Millions	Sep. 30, 2020	Dec. 31, 2019
Assets:
Marketable securities	$ 79	$ 62
Derivatives	1	$ 4
Recurring Fair Value Measurements
Assets:
Marketable securities	105
Derivatives	1
Total	106
Liabilities:
Derivatives	61
Contingent consideration	108
Total	169
Recurring Fair Value Measurements | Level 1
Assets:
Marketable securities	105
Derivatives	0
Total	105
Liabilities:
Derivatives	0
Contingent consideration	0
Total	0
Recurring Fair Value Measurements | Level 2
Assets:
Marketable securities	0
Derivatives	1
Total	1
Liabilities:
Derivatives	61
Contingent consideration	0
Total	61
Recurring Fair Value Measurements | Level 3
Assets:
Marketable securities	0
Derivatives	0
Total	0
Liabilities:
Derivatives	0
Contingent consideration	108
Total	$ 108

Fair Value Measurements - Chang

Fair Value Measurements - Changes in Level 3 Financial Assets and Liabilities Measured on Recurring Basis (Detail) - Contingent consideration - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation
Beginning balance	$ 113	$ 123
Business combinations	32	41
Contingent consideration paid	(22)	(44)
Revaluations included in earnings and foreign currency translation adjustments	(15)	(7)
Ending balance	$ 108	$ 113

Fair Value Measurements - Key A

Fair Value Measurements - Key Assumptions (Details)	Sep. 30, 2020
Revenue target
Fair Value Measurement Inputs and Valuation Techniques
Weighted average probability of target achievement	89.00%
Revenue target | Minimum
Fair Value Measurement Inputs and Valuation Techniques
Range of potential payment	0.00%
Revenue target | Maximum
Fair Value Measurement Inputs and Valuation Techniques
Range of potential payment	100.00%
EBITDA target
Fair Value Measurement Inputs and Valuation Techniques
Weighted average probability of target achievement	96.00%
EBITDA target | Minimum
Fair Value Measurement Inputs and Valuation Techniques
Range of potential payment	0.00%
EBITDA target | Maximum
Fair Value Measurement Inputs and Valuation Techniques
Range of potential payment	100.00%
Operational target
Fair Value Measurement Inputs and Valuation Techniques
Weighted average probability of target achievement	95.00%
Operational target | Minimum
Fair Value Measurement Inputs and Valuation Techniques
Range of potential payment	0.00%
Operational target | Maximum
Fair Value Measurement Inputs and Valuation Techniques
Range of potential payment	100.00%

Credit Arrangements - Summary o

Credit Arrangements - Summary of Credit Facilities (Detail)	9 Months Ended
	Sep. 30, 2020USD ($)	Sep. 30, 2020GBP (£)
Revolving Credit Facility | USD Revolving Credit Facility
Line of Credit Facility
Interest Rates	LIBOR in the relevant currency borrowed plus a margin of 1.50% at September 30, 2020
Facility	$ 1,500,000,000
Revolving Credit Facility | USD Revolving Credit Facility | LIBOR
Line of Credit Facility
Rate (percent)	1.50%	1.50%
Facility | Receivables Financing Facility
Line of Credit Facility
Interest Rates	LIBOR Market Index Rate (0.15% at September 30, 2020) plus 0.90%
Rate (percent)	0.15%	0.15%
Facility	$ 25,000,000
Facility | Receivables Financing Facility | LIBOR
Line of Credit Facility
Interest rate spread on base rate (percent)	0.90%
Facility | General Banking Facility
Line of Credit Facility
Interest Rates	Bank’s base rate of 0.10% at September 30, 2020 plus 1%
Rate (percent)	0.10%	0.10%
Facility	$ 13,000,000	£ 10,000,000
Facility | General Banking Facility | Base Rate
Line of Credit Facility
Interest rate spread on base rate (percent)	1.00%

Credit Arrangements - Summary_2

Credit Arrangements - Summary of Debt (Detail) € in Millions, $ in Millions	9 Months Ended
	Sep. 30, 2020USD ($)	Jun. 24, 2020EUR (€)	Dec. 31, 2019USD ($)
Senior Secured Credit Facilities:
Principal amount of debt	$ 12,410		$ 11,705
Less: unamortized discount and debt issuance costs	(71)		(60)
Less: current portion	(144)		(100)
Long-term debt	12,195		11,545
Due in 2028 | 2.875 Senior Notes | Senior Notes
Senior Secured Credit Facilities:
Principal amount of debt | €		€ 711
Rate (percent)		2.875%
U.S Dollars | Due in 2023 | Revolving Credit Facility | LIBOR
Senior Secured Credit Facilities:
Principal amount of debt	$ 0		154
Average floating rate	1.65%
U.S Dollars | Due in 2023 | Senior Secured Term A Loan | LIBOR
Senior Secured Credit Facilities:
Principal amount of debt	$ 739		770
Average floating rate	1.72%
U.S Dollars | Due in 2023 | Term A Loan due 2023—U.S. Dollar LIBOR at average floating rates of 2.75% | LIBOR
Senior Secured Credit Facilities:
Principal amount of debt	$ 778		0
Average floating rate	2.75%
U.S Dollars | Due in 2024 | Senior Secured Term B Loan | LIBOR
Senior Secured Credit Facilities:
Principal amount of debt	$ 535		535
Average floating rate	1.90%
U.S Dollars | Due in 2025 | Senior Secured Term B Loan | LIBOR
Senior Secured Credit Facilities:
Principal amount of debt	$ 728		733
Average floating rate	1.90%
U.S Dollars | Due in 2025 | Senior Secured Additional Term B Loan | LIBOR
Senior Secured Credit Facilities:
Principal amount of debt	$ 929		936
Average floating rate	1.97%
U.S Dollars | Due in 2027 | 5.0% Senior Notes | Senior Notes
Senior Secured Credit Facilities:
Principal amount of debt	$ 1,100		1,100
Rate (percent)	5.00%
U.S Dollars | Due in 2026 | 5.0% Senior Notes | Senior Notes
Senior Secured Credit Facilities:
Principal amount of debt	$ 1,050		1,050
Rate (percent)	5.00%
U.S Dollars | Due in 2022 | Receivables financing facility due 2022—U.S. Dollar LIBOR at average floating rates of 1.05% | LIBOR
Senior Secured Credit Facilities:
Principal amount of debt	$ 300		300
Rate (percent)	1.05%
EUR Dollars | Due in 2023 | Senior Secured Term A Loan | LIBOR
Senior Secured Credit Facilities:
Principal amount of debt	$ 388		387
Average floating rate	1.50%
EUR Dollars | Due in 2024 | Senior Secured Term B Loan | LIBOR
Senior Secured Credit Facilities:
Principal amount of debt	$ 1,354		1,306
Average floating rate	2.00%
EUR Dollars | Due in 2024 | 3.5% Senior Notes due 2024—Euro denominated | Senior Notes
Senior Secured Credit Facilities:
Principal amount of debt	$ 0		701
Rate (percent)	3.50%
EUR Dollars | Due in 2025 | Senior Secured Additional Term B Loan | LIBOR
Senior Secured Credit Facilities:
Principal amount of debt	$ 668		644
Average floating rate	2.00%
EUR Dollars | Due in 2025 | 2.875 Senior Notes | Senior Notes
Senior Secured Credit Facilities:
Principal amount of debt	$ 492		471
Rate (percent)	2.875%
EUR Dollars | Due in 2025 | 3.25% Senior Notes due 2025—Euro denominated | Senior Notes
Senior Secured Credit Facilities:
Principal amount of debt	$ 1,671		1,598
Rate (percent)	3.25%
EUR Dollars | Due in 2028 | 2.875 Senior Notes | Senior Notes
Senior Secured Credit Facilities:
Principal amount of debt	$ 834		0
Rate (percent)	2.875%
EUR Dollars | Due in 2028 | 3.5% Senior Notes due 2024—Euro denominated | Senior Notes
Senior Secured Credit Facilities:
Rate (percent)		3.50%
EUR Dollars | Due in 2028 | 2.25% Senior Notes due 2028—Euro denominated | Senior Notes
Senior Secured Credit Facilities:
Principal amount of debt	$ 844		808
Rate (percent)	2.25%
Japan, Yen | Revolving Credit Facility | LIBOR
Senior Secured Credit Facilities:
Principal amount of debt	$ 0		$ 212
Average floating rate	1.50%

Credit Arrangements - Contractu

Credit Arrangements - Contractual Maturities of Long-term Debt (Detail) - USD ($) $ in Millions	Sep. 30, 2020	Dec. 31, 2019
Debt Disclosure [Abstract]
Remainder of 2020	$ 36
2021	146
2022	446
2023	1,699
2024	1,867
Thereafter	8,216
Principal amount of debt	$ 12,410	$ 11,705

Credit Arrangements - Additiona

Credit Arrangements - Additional Information (Detail) € in Millions, £ in Millions	Jun. 24, 2020EUR (€)	Mar. 30, 2020USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2020GBP (£)	Mar. 11, 2020USD ($)	Dec. 31, 2019USD ($)
Line of Credit Facility
Outstanding borrowings			$ 12,410,000,000			$ 11,705,000,000
Standby Letters of Credit
Line of Credit Facility
Available borrowing capacity			1,500,000,000
General Banking Facility
Line of Credit Facility
Bank guarantees			1,100,000	£ 0.9
Senior Secured Credit Facilities
Line of Credit Facility
Aggregate maximum principal amount			7,600,000,000
Outstanding borrowings			6,100,000,000
Available borrowing capacity			1,500,000,000
TLA - 2 Loans | Secured Debt
Line of Credit Facility
Aggregate maximum principal amount					$ 900,000,000
Prepaid debt		$ 100,000,000
TLA - 2 Loans | Secured Debt | LIBOR
Line of Credit Facility
Interest rate spread on base rate (percent)		1.00%
TLA - 2 Loans | Secured Debt | LIBOR | Minimum
Line of Credit Facility
Interest rate spread on base rate (percent)		1.50%
TLA - 2 Loans | Secured Debt | LIBOR | Maximum
Line of Credit Facility
Interest rate spread on base rate (percent)		2.25%
2.875 Senior Notes | Senior Notes | Due in 2028
Line of Credit Facility
Outstanding borrowings | €	€ 711
Debt instrument interest rate stated percentage	2.875%
2.875 Senior Notes | Senior Notes | Due in 2028 | EUR Dollars
Line of Credit Facility
Outstanding borrowings			$ 834,000,000			0
Debt instrument interest rate stated percentage			2.875%
2.875 Senior Notes | Minimum | Senior Notes | Due in 2028
Line of Credit Facility
Redemption premium percentage	0.00%
2.875 Senior Notes | Maximum | Senior Notes | Due in 2028
Line of Credit Facility
Redemption premium percentage	1.438%
3.5% Senior Notes due 2024—Euro denominated | Senior Notes | Due in 2028 | EUR Dollars
Line of Credit Facility
Debt instrument interest rate stated percentage	3.50%
3.5% Senior Notes due 2024—Euro denominated | Senior Notes | Due in 2024 | EUR Dollars
Line of Credit Facility
Outstanding borrowings			$ 0			$ 701,000,000
Debt instrument interest rate stated percentage			3.50%

Stockholders' Equity - Narrativ

Stockholders' Equity - Narratives (Detail) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended				9 Months Ended
	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2020	Dec. 31, 2019
Class of Stock
Preferred stock, authorized (shares)					1,000,000
Preferred stock, par value (usd per share)					$ 0.01
Preferred stock, shares issued (shares)					0	0
Preferred stock, shares outstanding (shares)					0	0
Repurchase of stock, value	$ 332	$ 313	$ 236	$ 145
Equity Repurchase Under Repurchase Program
Class of Stock
Equity available for repurchase under the repurchase program					$ 1,000
Secondary Public Offering | Equity Repurchase Under Repurchase Program
Class of Stock
Repurchase of stock (shares)					2,106,403
Repurchase of stock, value					$ 321.4
Repurchased From Company Stockholders | Equity Repurchase Under Repurchase Program
Class of Stock
Repurchase of stock (shares)					1,000,000
Repurchase of stock, value					$ 164.3

Restructuring - Summary of Amou

Restructuring - Summary of Amounts Recorded for Restructuring Plans (Detail) $ in Millions	9 Months Ended
	Sep. 30, 2020USD ($)
Restructuring Reserve
Restructuring reserves, beginning balance	$ 67
Expense, net of reversals	50
Payments	(52)
Foreign currency translation and other	0
Restructuring reserves, ending balance	65
Severance and Related Costs
Restructuring Reserve
Restructuring reserves, beginning balance	64
Expense, net of reversals	50
Payments	(51)
Foreign currency translation and other	0
Restructuring reserves, ending balance	63
Facility Exit Costs
Restructuring Reserve
Restructuring reserves, beginning balance	3
Expense, net of reversals	0
Payments	(1)
Foreign currency translation and other	0
Restructuring reserves, ending balance	$ 2

Income Taxes - Narratives (Deta

Income Taxes - Narratives (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Income Tax Disclosure [Abstract]
Effective income tax rate (percent)	(2.90%)	(1.40%)	5.00%	18.80%
Federal consolidated income tax returns			$ 24
Tax impact of share-based compensation awards	$ 9	$ 3	35	$ 20
Discrete tax expense			$ 10
Tax benefit recorded in 2018				$ 20

Comprehensive Income (Loss) - S

Comprehensive Income (Loss) - Summary of Components of AOCI (Detail)	9 Months Ended
	Sep. 30, 2020USD ($)
Statement of Other Comprehensive Income
Beginning balance	$ 6,003,000,000
Reclassification adjustments	6,000,000
Ending balance	5,846,000,000
Beginning balance	156,000,000
Other comprehensive income (loss) before reclassifications	94,000,000
Other comprehensive income (loss) before reclassifications	(12,000,000)
Reclassification adjustments, tax	(2,000,000)
Ending balance	248,000,000
Foreign Currency Translation
Statement of Other Comprehensive Income
Beginning balance	(430,000,000)
Other comprehensive income (loss) before reclassifications	(62,000,000)
Reclassification adjustments	0
Ending balance	(492,000,000)
Derivative Instruments
Statement of Other Comprehensive Income
Beginning balance	(21,000,000)
Other comprehensive income (loss) before reclassifications	(44,000,000)
Reclassification adjustments	8,000,000
Ending balance	(57,000,000)
Defined Benefit Plans
Statement of Other Comprehensive Income
Beginning balance	(16,000,000)
Other comprehensive income (loss) before reclassifications	0
Reclassification adjustments	0
Ending balance	(16,000,000)
Accumulated Other Comprehensive (Loss) Income
Statement of Other Comprehensive Income
Beginning balance	(311,000,000)
Ending balance	$ (317,000,000)

Comprehensive Income (Loss) -_2

Comprehensive Income (Loss) - Summary of Adjustments for (Gains) Losses Reclassified from AOCI into Condensed Consolidated Statements of Income and Affected Financial Statement Line Item (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Reclassification Adjustment out of Accumulated Other Comprehensive Income
Total before income taxes	$ 3	$ 2	$ 8	$ (3)
Income tax (benefit) expense	1	0	2	(1)
Total net of income taxes	2	2	6	(2)
Foreign exchange forward contracts | Revenues
Reclassification Adjustment out of Accumulated Other Comprehensive Income
Total before income taxes	4	2	9	3
Foreign exchange forward contracts | Other expense (income), net
Reclassification Adjustment out of Accumulated Other Comprehensive Income
Total before income taxes	$ (1)	$ 0	$ (1)	$ (6)

Segments - Additional Informati

Segments - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2020Segment
Segment Reporting [Abstract]
Number of reportable segments	3

Segments - Operations by Report

Segments - Operations by Reportable Segments (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Segment Reporting Information
Revenues	$ 2,786	$ 2,769	$ 8,061	$ 8,193
Costs of revenue, exclusive of depreciation and amortization	1,800	1,852	5,328	5,399
Selling, general and administrative expenses	460	395	1,298	1,250
Segment profit	600	563	1,596	1,681
Depreciation and amortization	(319)	(299)	(943)	(888)
Restructuring costs	(20)	(19)	(50)	(45)
Income from operations	187	204	442	611
Technology & Analytics Solutions
Segment Reporting Information
Revenues	1,207	1,095	3,433	3,272
Costs of revenue, exclusive of depreciation and amortization	727	667	2,048	1,956
Segment profit	292	261	836	777
Research & Development Solutions
Segment Reporting Information
Revenues	1,400	1,466	4,076	4,317
Costs of revenue, exclusive of depreciation and amortization	925	1,007	2,811	2,924
Segment profit	291	287	721	864
Contract Sales & Medical Solutions
Segment Reporting Information
Revenues	179	208	552	604
Costs of revenue, exclusive of depreciation and amortization	148	178	469	519
Segment profit	17	15	39	40
Operating Segments | Technology & Analytics Solutions
Segment Reporting Information
Selling, general and administrative expenses	188	167	549	539
Operating Segments | Research & Development Solutions
Segment Reporting Information
Selling, general and administrative expenses	184	172	544	529
Operating Segments | Contract Sales & Medical Solutions
Segment Reporting Information
Selling, general and administrative expenses	14	15	44	45
General corporate and unallocated
Segment Reporting Information
Selling, general and administrative expenses	74	41	161	137
Segment profit	$ (74)	$ (41)	$ (161)	$ (137)

Earnings Per Share - Summary of

Earnings Per Share - Summary of Weighted-Average Outstanding Stock-Based Awards Excluded from Computation of Diluted Earnings Per Share (Detail) - shares shares in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share
Total shares excluded from diluted earnings per share	2.2	1.7	2.5	2
Shares subject to performance conditions
Antidilutive Securities Excluded from Computation of Earnings Per Share
Total shares excluded from diluted earnings per share	1.1	1.3	1.2	1.3
Shares subject to anti-dilutive stock-based awards
Antidilutive Securities Excluded from Computation of Earnings Per Share
Total shares excluded from diluted earnings per share	1.1	0.4	1.3	0.7